Efficacy and Safety comparison of Sitagliptin and Glimepiride in elderly Japanese patients with type 2 diabetes - START-J: SiTAgliptin in eldeRly Trial in Japan

Japan Association for Diabetes Education and Care0 个研究点目标入组 900 人开始时间: 2010年8月16日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Active proliferative retinopathy or maculopathy requiring treatment 2.Liver dysfunction (>x2 of upper normal limit), moderate or severe renal dysfunction(serum Cr>1.5mg/dL in male, Cr>1.3mg/dL in female, GFR<30), severe cardiac disease (NYHA III or IV), malignancy or uncontrolled hypertension (treated or untreated) as judged by the Investigator 3.Mental incapacity (including moderate or severe dementia) precluding adequate understanding and/or cooperation as judged by the Investigator 4.Recurrent hypoglycaemia or hypoglycaemic unawareness as judged by the investigator 5.Previous history of severe allergy to pharmaceutical products 6.Systemic glucocorticoids users or potential users 7.Suspected type 1 diabetes (including SPIDDM) or positive anti-GAD antibody 8.Any condition that the investigator considers a potential obstacle to trial participation and/or data analysis

发起方